| Expression pattern: |
UP |
| Associated gene: |
CPS1 / carbamoyl phosphate synthetase 1 |
| Associated microRNA: |
- |
| Biological function: |
circSETD2 promotes FFA-induced lipid accumulation and lipogenesis, suppresses fatty acid beta-oxidation, and exacerbates lipid metabolic disturbances and MAFLD progression. |
| Molecular mechanism: |
circSETD2 directly binds CPS1 and reduces CPS1 enzymatic activity, thereby impairing CPS1-mediated regulation of lipid homeostasis. |
| Biological pathway or process: |
other pathway/process (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; circRNA-seq; RT-qPCR; FISH / smFISH; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Transfection; Oil Red O Staining; Western Blot; Bioinformatics Analysis; RNA-seq |
| Clinical significance: |
circSETD2 is positioned as a promising prognostic biomarker and therapeutic target for MAFLD. |
| Description: |
Human circSETD2 is a SETD2-derived circRNA significantly upregulated in MAFLD patient liver tissues and FFA-treated HepG2 cells. It promotes lipid metabolic dysregulation by binding CPS1 and reducing CPS1 enzymatic activity, thereby increasing lipogenesis and lipid accumulation while suppressing fatty acid beta-oxidation. |
| Confidence score: |
0.8335 |